A naukri.com initiative
Bioengineer
2w
138
Image Credit: Bioengineer
Innovative Therapies Target Advanced-Stage Retinal Degenerations
- Researchers at the University of Pennsylvania have developed novel photoreceptor-specific promoters for gene therapy targeting advanced-stage retinal degenerations, addressing a key challenge in ocular gene therapy.
- Inherited retinal degenerations involve the progressive loss of photoreceptors, leading to vision impairment and blindness due to mutations in critical genes for cellular function and survival.
- Current gene therapy approaches face limitations in delivering targeted gene expression in degenerating photoreceptors, especially in advanced disease stages.
- The research team identified and validated four potent promoters that remain active even after over 50% photoreceptor loss, surpassing existing promoter systems in efficacy.
- These compact promoters are compatible with adeno-associated virus (AAV) vectors, overcoming packaging constraints and improving specificity for photoreceptors to minimize off-target effects.
- Using large-animal models resembling human retinal degeneration, the study demonstrates translational relevance and potential therapeutic benefits for both human and veterinary ophthalmology.
- The development of these promoters signifies a shift towards designing gene therapies for the entire spectrum of disease progression, offering hope for improved treatments in advanced-stage retinal diseases.
- The research team's multidisciplinary expertise and provisional patent application highlight the commercial and clinical potential of these promoters in advancing ocular gene therapy.
- By enhancing design flexibility for AAV vectors, these promoters could enable more advanced molecular interventions targeting inherited retinal degenerations and other retinal disorders.
- This groundbreaking work not only advances scientific understanding but also provides tangible hope for patients with limited treatment options, bridging the gap between early-stage promise and advanced-stage efficacy.
Read Full Article
8 Likes
For uninterrupted reading, download the app